LSP PROJECT REPORT DEVELOPMENT OF HEPG CELL LINE WITH HUMAN NTCP GENE
No Thumbnail Available
Date
2024
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Nazarbayev University School of Medicine
Abstract
Hepatitis B virus (HBV) is one of the most common viral infections of the liver. There are 296 million people around the world with chronic hepatitis B and 1.5 million new cases emerge each year (WHO on Hepatitis B, 2021). Also, complications of hepatitis B virus such as liver cirrhosis and hepatocellular carcinoma were the cause of 820 000 deaths in 2019. It creates a significant economic and social burden, especially in developing countries. Until the 2010s the proper mechanism of viral internalization of hepatitis B virus was not properly understood. However, discovery of Na+-taurocholate cotransporting polypeptide (NTCP) protein allowed better understanding of the process as well as new possibilities in treatment. Common anti-HBV treatment is usually antiretroviral utilizing its usage of reverse transcriptase. The discovery of a specific viral entry point may allow development of new treatment options. However, expression of NTCP is downregulated in in vitro hepatocytes. This poses an obstacle in creating a testing field for medication options. Sadly, during this research the results were not achieved due to shortage of time and difficulties with competent cells.
Description
Keywords
Type of access:, Hepatitis B virus
Citation
Irgaliyev, A. (2024). LSP project report Development of HepG cell line with human NTCP gene. Nazarbayev University School of Medicine